We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Fetuin‐A, inter‐α‐trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes.
- Authors
Reverté, Laia; Yeregui, Elena; Olona, Montserrat; Gutiérrez‐Valencia, Alicia; Buzón, Maria José; Martí, Anna; Gómez‐Bertomeu, Frederic; Auguet, Teresa; López‐Cortés, Luis F.; Burgos, Joaquin; Benavent‐Bofill, Clara; Boqué, Carme; García‐Pardo, Graciano; Ruiz‐Mateos, Ezequiel; Mestre, Maria Teresa; Vidal, Francesc; Viladés, Consuelo; Peraire, Joaquim; Rull, Anna
- Abstract
Fetuin-A, inter- -trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes (B) Receiver operating characteristic (ROC) curves analysis for the predictive power of top selected protein-encoding genes, lipids and metabolites in random forest analysis to differentiate patients with mild from those with a critical illness. Our COVID-19 study cohort included 273 SARS-CoV-2 infected individuals recruited during the first wave (March-April 2020) in three different hospitals and grouped by the disease severity following the medical inclusion criteria3 in mild, severe or critical (Figure 1A), from whom demographic, preexisting clinical conditions and COVID-19 treatments are summarized in Table S1. Dear Editor, The mechanistic pathways leading to immune dysregulation and complications driven by uncontrolled severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection remain major challenges.1,2 Hence, a detailed analysis of the proteome, metabolome and lipidome profile of coronavirus disease 2019 (COVID-19) patients showing different severity grades might shed light on the disease pathophysiology and unveil new predictive biomarkers to promptly ascertain patient's outcomes.
- Subjects
COVID-19; GLUTAMIC acid; SARS-CoV-2; CHOLESTERYL ester transfer protein; AMINO acid metabolism; TRYPSIN
- Publication
Clinical & Translational Medicine, 2022, Vol 12, Issue 1, p1
- ISSN
2001-1326
- Publication type
Article
- DOI
10.1002/ctm2.704